ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,361.92
0.44%
Gold vs US Dollar
2,651.44
-0.79%
Brent Oil
71.515
0.80%
Bitcoin
66,032.63
1.30%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Seres Therapeutics Inc (MCRB)

  7. Seres Therapeutics Inc (MCRB) News

Seres Therapeutics (MCRB)

Seres Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MCRB
DateTimeSourceHeadlineSymbolCompany
26/09/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
26/09/202421:01GlobeNewswire Inc.Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30NASDAQ:MCRBSeres Therapeutics Inc
13/09/202412:00GlobeNewswire Inc.Seres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
12/09/202413:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
12/09/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
12/09/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
12/09/202412:00GlobeNewswire Inc.Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)NASDAQ:MCRBSeres Therapeutics Inc
26/08/202421:36Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:MCRBSeres Therapeutics Inc
19/08/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
19/08/202422:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
19/08/202422:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
19/08/202422:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
19/08/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
15/08/202421:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
15/08/202411:52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:MCRBSeres Therapeutics Inc
15/08/202411:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
13/08/202422:21Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
13/08/202415:38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MCRBSeres Therapeutics Inc
13/08/202412:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
13/08/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
13/08/202412:00GlobeNewswire Inc.Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
07/08/202413:38Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
06/08/202422:28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
06/08/202422:28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
06/08/202422:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
06/08/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
06/08/202412:41Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
06/08/202412:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
06/08/202412:00GlobeNewswire Inc.Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024NASDAQ:MCRBSeres Therapeutics Inc
06/08/202412:00GlobeNewswire Inc.Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health ScienceNASDAQ:MCRBSeres Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MCRB

Your Recent History

EU
RUI
Rubis
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved